Main > ONCOLOGY (**) > Breast Cancer>MET *** > Treatment > Co: USA. A. BevacizuMAb BioSimilar+

---

Co: USA. A. BevacizuMAb BioSimilar+'s subsections
(*) EU Approval Date: 2018. 01.18
(*) USA Approval Year: 2017.
+Paclitaxel
Company
TradeMark
TradeMark Web-Site

Co: USA. A. BevacizuMAb BioSimilar+'s products
This section has no products